

Granisetron

Granisetron dosing may be weight based; ensure accuracy of documented weight before administration		
Form	1mg/mL solution for injection	Store below 25°C
Reconstitution	Already in solution The solution should be clear and colourless. Inspect visually for particulate matter or discoloration prior to administration and discard if present. • Draw up using a 5 micron filter needle • Use gloves when opening ampoules Dilute further before administration	
Compatibility & Stability	Sodium Chloride 0.9% Glucose 5%	
Administration	IV Injection	
	Withdraw the required dose and dilute each 1 mg (1 mL) to 5 mL with sodium chloride 0.9% in the syringe. Give by IV injection over a minimum of 30 seconds.	
	IV Infusion	
	Intravenous infusion diluted in 20 to 50 mL of compatible infusion fluid and administered over 5 minutes.	
Monitoring	Acute reactions: • hypersensitivity reactions (such as anaphylaxis and urticaria) • headache • rash • ECG changes including QT prolongation - use cautiously in patients with cardiac co-morbidities, on cardiotoxic chemotherapy and/or with concomitant electrolyte abnormalities. Monitor ECG in patients concomitantly taking medicines known to prolong the QT interval.	
Extravasation	Granisetron has a low pH and may cause venous irritation and tissue damage in cases of extravasation.	

Information relates to Kytril (Atrahs Pharma) last updated 16/4/26